Okke de Weerdt

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

Monique Terwijn, Wim L.J. van Putten, Angèle Kelder et al. · Journal of Clinical Oncology · 2013 · 449 citations · Full text

Medicine, Hematology, Oncology +16

Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome

Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders et al. · Blood · 2022 · 290 citations · Full text

Medicine, Hematology, Molecular Genetics +17

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman et al. · Blood · 2009 · 275 citations · Full text

Medicine, Hematology, Oncology +17

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients

Gerwin Huls, Dana Chiţu, Violaine Havelange et al. · Blood · 2019 · 176 citations · Full text

Medicine, Oncology, Pharmacology +3

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld et al. · Haematologica · 2007 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14